Drugs / 68Ga-NI-FAPI
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06688305 | Aug 2024 → Jul 2025 overdue | cancer | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07464132 | Dec 2025 → Feb 2027 expected | hypertrophic cardiomyopathy, neoplasm, pulmonary fibrosis, vasculitis | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NI-FAPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06688305 ↗ |
| Modality | Diagnostic / imaging agent | “[68Ga]Ga-NI-FAPI-04 PET/CT Imaging” NCT07464132 ↗ |
| Route | Intravenous | “after intravenous administration of 68Ga-NI-FAPI.” NCT06688305 ↗ |